Cyclosporine and long-term kidney graft survival

被引:45
作者
Opelz, G [1 ]
Döhler, B [1 ]
机构
[1] Univ Heidelberg, Inst Immunol, Dept Transplantat Immunol, D-69120 Heidelberg, Germany
关键词
D O I
10.1097/00007890-200110150-00015
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Previous analysis of kidney transplant data from the Collaborative Transplant Study database showed that patients receiving cyclosporine 3-6 mg/kg/day 1 year posttransplantation had the best graft survival rate 7 years posttransplantation. Longer-term and additional analyses have now been performed. Methods. Data from cadaver kidney transplants performed between 1985 and 1998 were analyzed retrospectively. Patients were included if they had a functioning graft 1 year posttransplantation, and the daily cyclosporine dose administered 1 year posttransplantation was reported. Data on cyclosporine dose, serum creatinine concentration, and systolic blood pressure were recorded 1 and 5 years after transplantation; information on graft survival was documented at yearly intervals. Results. Patients receiving cyclosporine 3-6 mg/kg/ day 1 year posttransplantation had the best graft survival rate 10 years posttransplantation. Cyclosporine <2 mg/kg/day was least beneficial overall and in subanalyses based on age, risk level, and 1-year serum creatinine concentration. The microemulsion cyclosporine formulation (Neoral) was associated with a significantly higher 4-year graft survival rate than the conventional formulation (Sandimmune; P=0.0001). Median systolic blood pressure 5 years posttransplantation was similar in each 1-year cyclosporine dose category (range of medians 139.0-140.0 mmHg). The percentages of patients with serum creatinine concentrations of <130, 130-260, 260-400, or >400 mu mol/L 1 and 5 years posttransplantation were similar across 1-year cyclosporine dose categories, with the exception of >6 mg/kg/day, where there was a shift toward a less favorable serum creatinine concentration over time. Conclusions. The 1-year cyclosporine dose was significantly associated with long-term graft survival, with evidence of underimmunosuppression at doses <3 mg/kg/day and overimmunosuppression at doses > 6 mg/kg/day, but had little influence on systolic blood pressure or serum creatinine concentration at doses up to 6 mg/kg/day.
引用
收藏
页码:1267 / 1273
页数:7
相关论文
共 15 条
[1]   RISK-FACTORS FOR CHRONIC REJECTION IN RENAL-ALLOGRAFT RECIPIENTS [J].
ALMOND, PS ;
MATAS, A ;
GILLINGHAM, K ;
DUNN, DL ;
PAYNE, WD ;
GORES, P ;
GRUESSNER, R ;
NAJARIAN, JS ;
FERGUSON ;
PAUL ;
SCHAFFER .
TRANSPLANTATION, 1993, 55 (04) :752-757
[2]  
Barama A, 2000, TRANSPLANTATION, V69, pS162
[3]  
DIEPERINK H, 1989, DAN MED BULL, V36, P235
[4]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[5]  
Levy GA, 2000, TRANSPLANTATION, V69, pS387
[6]   INFLUENCE OF CYCLOSPORINE PHARMACOKINETICS, TROUGH CONCENTRATIONS, AND AUC MONITORING ON OUTCOME AFTER KIDNEY-TRANSPLANTATION [J].
LINDHOLM, A ;
KAHAN, BD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (02) :205-218
[7]   PHARMACOKINETICS AND TOLERABILITY OF A MICROEMULSION FORMULATION OF CYCLOSPORINE IN RENAL-ALLOGRAFT RECIPIENTS - A CONCENTRATION-CONTROLLED COMPARISON WITH THE COMMERCIAL FORMULATION [J].
MUELLER, EA ;
KOVARIK, JM ;
VANBREE, JB ;
LISON, AE ;
KUTZ, K .
TRANSPLANTATION, 1994, 57 (08) :1178-1182
[9]   Relationship between maintenance dose of cyclosporine and long-term kidney graft survival [J].
Opelz, G .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (05) :1716-1717
[10]  
Opelz G, 2000, TRANSPLANTATION, V69, P818